$NTRA
Natera, Inc.

2021 Q1 Form 10-Q Financial Statement

#000155837021006346 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $152.3M $94.01M
YoY Change 62.02% 40.69%
Cost Of Revenue $66.80M $41.52M
YoY Change 60.89% -0.2%
Gross Profit $85.50M $52.49M
YoY Change 62.88% 123.17%
Gross Profit Margin 56.13% 55.84%
Selling, General & Admin $108.3M $65.68M
YoY Change 64.94% 49.85%
% of Gross Profit 126.7% 125.13%
Research & Development $40.19M $18.23M
YoY Change 120.51% 59.38%
% of Gross Profit 47.0% 34.72%
Depreciation & Amortization $2.549M $1.826M
YoY Change 39.59% -4.9%
% of Gross Profit 2.98% 3.48%
Operating Expenses $148.5M $83.91M
YoY Change 77.01% 51.82%
Operating Profit -$63.02M -$34.87M
YoY Change 80.71% 9.85%
Interest Expense $2.073M $2.464M
YoY Change -15.87% -9.54%
% of Operating Profit
Other Income/Expense, Net $1.400M $2.000M
YoY Change -30.0% 300.0%
Pretax Income -$63.72M -$35.35M
YoY Change 80.26% 3.92%
Income Tax $134.0K $23.00K
% Of Pretax Income
Net Earnings -$63.85M -$35.37M
YoY Change 80.52% 3.76%
Net Earnings / Revenue -41.92% -37.62%
Basic Earnings Per Share -$0.74
Diluted Earnings Per Share -$0.74 -$452.1K
COMMON SHARES
Basic Shares Outstanding 86.69M 78.25M
Diluted Shares Outstanding 86.69M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $653.6M $405.8M
YoY Change 61.06% 216.78%
Cash & Equivalents $65.13M $74.10M
Short-Term Investments $588.4M $331.7M
Other Short-Term Assets $26.60M $15.70M
YoY Change 69.43% 161.67%
Inventory $23.68M $14.16M
Prepaid Expenses
Receivables $87.56M $61.58M
Other Receivables $0.00 $0.00
Total Short-Term Assets $791.4M $497.2M
YoY Change 59.17% 138.93%
LONG-TERM ASSETS
Property, Plant & Equipment $40.18M $26.72M
YoY Change 50.37% -47.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.41M $12.09M
YoY Change 2.59% 331.89%
Total Long-Term Assets $102.1M $61.43M
YoY Change 66.22% 15.26%
TOTAL ASSETS
Total Short-Term Assets $791.4M $497.2M
Total Long-Term Assets $102.1M $61.43M
Total Assets $893.5M $558.6M
YoY Change 59.94% 113.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.682M $8.369M
YoY Change -44.06% -5.97%
Accrued Expenses $77.30M $50.39M
YoY Change 53.39% 34.02%
Deferred Revenue $9.069M $51.84M
YoY Change -82.51%
Short-Term Debt $50.10M $50.10M
YoY Change 0.0% -0.2%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $167.0M $176.6M
YoY Change -5.48% 56.74%
LONG-TERM LIABILITIES
Long-Term Debt $279.5M $72.90M
YoY Change 283.4% -0.68%
Other Long-Term Liabilities $74.60M $310.0K
YoY Change 23964.52% -99.56%
Total Long-Term Liabilities $354.1M $310.0K
YoY Change 114125.81% -99.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $167.0M $176.6M
Total Long-Term Liabilities $354.1M $310.0K
Total Liabilities $521.1M $299.7M
YoY Change 73.86% 16.85%
SHAREHOLDERS EQUITY
Retained Earnings -$987.0M -$734.9M
YoY Change 34.3% 5.11%
Common Stock $1.356B $988.2M
YoY Change 37.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $372.4M $258.9M
YoY Change
Total Liabilities & Shareholders Equity $893.5M $558.6M
YoY Change 59.94% 113.71%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$63.85M -$35.37M
YoY Change 80.52% 3.76%
Depreciation, Depletion And Amortization $2.549M $1.826M
YoY Change 39.59% -4.9%
Cash From Operating Activities -$74.88M -$35.10M
YoY Change 113.32% 10.31%
INVESTING ACTIVITIES
Capital Expenditures $10.26M $7.917M
YoY Change 29.59% 729.01%
Acquisitions
YoY Change
Other Investing Activities $97.00M $51.41M
YoY Change 88.68% 270.66%
Cash From Investing Activities $86.74M $43.49M
YoY Change 99.44% 236.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.570M 3.826M
YoY Change 19.45% 48.41%
NET CHANGE
Cash From Operating Activities -74.88M -35.10M
Cash From Investing Activities 86.74M 43.49M
Cash From Financing Activities 4.570M 3.826M
Net Change In Cash 16.43M 12.22M
YoY Change 34.51% -174.85%
FREE CASH FLOW
Cash From Operating Activities -$74.88M -$35.10M
Capital Expenditures $10.26M $7.917M
Free Cash Flow -$85.14M -$43.02M
YoY Change 97.91% 31.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3227000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-99000
CY2020Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
9562000
CY2021Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87430000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86223000
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Natera, Inc.
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001604821
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
31000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3080000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3826000
CY2021Q1 dei Entity File Number
EntityFileNumber
001-37478
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65126000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48668000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
163000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
187000
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
588446000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
688606000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2970000
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0894487
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
13011 McCallen Pass
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building A Suite 100
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78753
CY2021Q1 dei City Area Code
CityAreaCode
650
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
249-9090
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
NTRA
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
87943997
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
87562000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
78565000
CY2021Q1 us-gaap Inventory Net
InventoryNet
23676000
CY2020Q4 us-gaap Inventory Net
InventoryNet
20031000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
26430000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
26606000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
791403000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
862663000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40177000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33348000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49526000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21399000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12406000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14743000
CY2021Q1 us-gaap Assets
Assets
893512000
CY2020Q4 us-gaap Assets
Assets
932153000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4682000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8096000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25870000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
30371000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
77296000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
60407000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9069000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
50125000
CY2021Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
50052000
CY2020Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
50054000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
166969000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
199053000
CY2021Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
279471000
CY2020Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
202493000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23816000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
22805000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
893512000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
932153000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
152316000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50811000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21246000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
320000
CY2021Q1 us-gaap Liabilities
Liabilities
521067000
CY2020Q4 us-gaap Liabilities
Liabilities
445917000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87430000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86223000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
9000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1356212000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1411286000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-986973000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-929318000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3197000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4259000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
372445000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
486236000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94012000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40188000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18225000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
108332000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
65681000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
215333000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
128884000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-63017000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34872000
CY2021Q1 us-gaap Interest Expense
InterestExpense
2073000
CY2020Q1 us-gaap Interest Expense
InterestExpense
2464000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1371000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1987000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63719000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35349000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
134000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-63853000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-35372000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1062000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4747000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64915000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30625000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86689000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78287000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
278711000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7418000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
4747000
CY2020Q1 ntra Cumulative Effect Of New Accounting Principle In Period Of Adoption Duration
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionDuration
-403000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-35372000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
258927000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
486236000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4570000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23232000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-1062000
CY2021Q1 ntra Cumulative Effect Of New Accounting Principle In Period Of Adoption Duration
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionDuration
-76678000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-63853000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
372445000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-63853000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-35372000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2549000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1826000
CY2021Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
2097000
CY2020Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
721000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
23232000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7417000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2671000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1940000
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
304000
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
121000
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
316000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
-64000
CY2021Q1 ntra Other Non Cash Benefits Charges
OtherNonCashBenefitsCharges
56000
CY2020Q1 ntra Other Non Cash Benefits Charges
OtherNonCashBenefitsCharges
-57000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1387000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8997000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8786000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3966000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1703000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3310000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
217000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4501000
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-135000
CY2021Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
18602000
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3348000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-40045000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2832000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74876000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35100000
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
43024000
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
53876000
CY2020Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
11500000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
140024000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
93785000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10260000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7917000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
86740000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43492000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4570000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3826000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4570000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3826000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
16434000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12218000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48855000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61981000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65289000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74199000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
152000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
2343000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1898000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2657000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-63900000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-987000000.0
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65300000
CY2021Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
588400000
CY2021Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
50100000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:40.3pt;margin:0pt;">The preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts calculated based on the average selling price expected to be received from insurance payors, the operating right-of-use assets and the associated </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">lease liabilities, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, the valuation of the Convertible Notes, stock-based compensation, the fair value of common stock, income tax uncertainties, and the expected consideration to be received from contracts with customers. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.</p>
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
4220000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
110000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
4110000
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, and the full extent and duration of the impact of the COVID-19 pandemic on its business, its operations, and the global economy as a whole is not yet known. While the Company’s test volumes grew during the three months ended March 31, 2021, the overall average selling<span style="color:#ff0000;"> </span>prices for its tests decreased in the three months ended March 31, 2021 compared to the three months ended March 31, 2020, the Company cannot predict the potential nature, magnitude and duration of the effects of the COVID-19 pandemic on the macroeconomic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, accounts receivable and investments. The Company limits its exposure to credit loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company performs evaluations of financial conditions for insurance carriers, patients, clinics and laboratory partners and generally does not require collateral to support credit sales. For the three months ended March 31, 2021, and 2020, there were no customers exceeding 10% of total revenues on an individual basis. As of March 31, 2021 and December 31, 2020, there were no customers with an outstanding balance exceeding 10% of net accounts receivable. </p>
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4259000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
919000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3197000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5666000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
152316000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94012000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
152316000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94012000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
87562000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
78565000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9069000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
50125000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23816000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
22805000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32885000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
72930000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
72930000
CY2021Q1 ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
1030000
CY2021Q1 ntra Contract With Customer Liability Refunds Of Revenues Previously Deferred
ContractWithCustomerLiabilityRefundsOfRevenuesPreviouslyDeferred
10000000
CY2021Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-30292000
CY2021Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-783000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32885000
CY2021Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-30300000
CY2021Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
22
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
250457000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
251028000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
334792000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
337418000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
585249000
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
588446000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
92780000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
83402000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
52603000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
50054000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40177000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33348000
CY2021Q1 us-gaap Depreciation
Depreciation
2500000
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2373000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2260000
CY2021Q1 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
10520000
CY2020Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
12686000
CY2021Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3709000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
9635000
CY2021Q1 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
9268000
CY2020Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
5790000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25870000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
30371000
CY2021Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
20304000
CY2020Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17366000
CY2021Q1 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
5180000
CY2020Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
5141000
CY2021Q1 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
9247000
CY2020Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
2720000
CY2021Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
4815000
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3325000
CY2021Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
8601000
CY2020Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
4189000
CY2021Q1 ntra Accrued Shipping Charges
AccruedShippingCharges
2475000
CY2020Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
1604000
CY2021Q1 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
1151000
CY2020Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
1723000
CY2021Q1 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
4701000
CY2020Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
2355000
CY2021Q1 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
1940000
CY2020Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
2353000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6049000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7300000
CY2021Q1 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1803000
CY2020Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1691000
CY2021Q1 ntra Accrued Interest
AccruedInterest
2695000
CY2020Q4 ntra Accrued Interest
AccruedInterest
1078000
CY2021Q1 ntra Deposits Held For Sublease
DepositsHeldForSublease
320000
CY2021Q1 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
8015000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
77296000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
60407000
CY2020Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17366000
CY2019Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
9410000
CY2021Q1 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
5594000
CY2020Q1 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
4684000
CY2021Q1 ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
1403000
CY2020Q1 ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
1468000
CY2021Q1 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
1253000
CY2020Q1 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
1027000
CY2021Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
20304000
CY2020Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
11599000
CY2021Q1 ntra Noncash Investing Activities Related To Right Of Use Assets
NoncashInvestingActivitiesRelatedToRightOfUseAssets
29700000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6049000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50811000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
56860000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0751
CY2021Q1 us-gaap Lease Cost
LeaseCost
2700000
CY2020Q1 us-gaap Lease Cost
LeaseCost
1900000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2500000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2200000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7519000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10289000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10953000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11795000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
12119000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
20019000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
72694000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15834000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
56860000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11500000
CY2021Q1 us-gaap Purchase Obligation
PurchaseObligation
70602000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
134000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2021Q1 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
12200000
CY2021Q1 ntra Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-63853000
CY2020Q1 ntra Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-35372000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86689000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78287000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18424000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12722000

Files In Submission

Name View Source Status
0001558370-21-006346-index-headers.html Edgar Link pending
0001558370-21-006346-index.html Edgar Link pending
0001558370-21-006346.txt Edgar Link pending
0001558370-21-006346-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntra-20210331.xsd Edgar Link pending
ntra-20210331x10q.htm Edgar Link pending
ntra-20210331x10q_htm.xml Edgar Link completed
ntra-20210331xex31d1.htm Edgar Link pending
ntra-20210331xex31d2.htm Edgar Link pending
ntra-20210331xex32d1.htm Edgar Link pending
ntra-20210331xex32d2.htm Edgar Link pending
ntra-20210331_cal.xml Edgar Link unprocessable
ntra-20210331_def.xml Edgar Link unprocessable
ntra-20210331_lab.xml Edgar Link unprocessable
ntra-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending